Zomedica Corp. reported significant financial performance improvements in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated net revenue of $9.5 million for the three months ended June 30, 2026, marking a 37% increase from $7.0 million in the same period last year. For the first half of 2026, revenue reached $18.3 million, up 36% from $13.5 million in the prior year. This growth was attributed to increased sales of consumables and capital products, particularly from the PulseVet® and TRUFORMA® platforms, as well as contract manufacturing and engineering services.
Despite the revenue growth, Zomedica reported a net loss of $3.8 million for the second quarter of 2026, a notable reduction from a loss of $7.4 million in the same quarter of 2025. The loss for the first half of 2026 was $8.3 million, down from $71.2 million in the previous year, primarily due to the absence of significant impairment charges that had impacted the prior year's results. The company’s gross profit margin for the quarter was 64%, slightly down from 67% in the previous year, reflecting changes in product mix and increased operational costs.
Operationally, Zomedica has made strides in expanding its product offerings and market presence. The company launched new assays for its TRUFORMA® platform, contributing to revenue growth. Additionally, Zomedica's customer base has expanded, with U.S. revenue increasing to $7.9 million in Q2 2026 from $5.6 million in Q2 2025. The company also reported a rise in trade receivables, indicating increased sales activity. As of June 30, 2026, Zomedica had cash and cash equivalents of $7.2 million, down from $9.0 million at the end of 2025, alongside available-for-sale securities totaling $36.9 million.
Zomedica's strategic focus includes enhancing its product lines and expanding its market reach. The company has entered into agreements with Brisby Inc. and Cresilon, Inc. to develop and market new products, which are expected to bolster future revenue streams. The company anticipates continued revenue growth as it ramps up sales and marketing efforts. However, Zomedica also acknowledges the potential for ongoing net losses until revenues sufficiently cover operating expenses. The company remains committed to managing its cash flow and operational costs while pursuing growth opportunities in the veterinary health sector.
About Zomedica Corp.
Zomedica Corp. is an animal health company developing and marketing diagnostic and therapeutic products for companion animals and horses. Its portfolio includes innovative diagnostics, digital microscopy, remote monitoring, and pain/inflammation treatment devices. Serving veterinarians and pet owners globally, Zomedica focuses on improving animal care, practice efficiency, and profitability through proprietary technologies, strategic acquisitions, and a diversified product pipeline.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov